readthroughSign in
Jul 7, 2026Trial update

Tiziana registers Phase 2a "BANYAN" trial of nasal foralumab in ALS

Tiziana Life Sciences listed a new Phase 2a study testing nasal foralumab's safety and immune effects in ALS patients, with the trial not yet recruiting.

Tiziana Life Sciences had one new registry item posted this week, a Phase 2a ALS study under its MyMatch platform.

  • "BANYAN," a Phase 2a randomized, double-blind trial (NCT07688239, sponsor ID TILS-ALS-01) sponsored by Tiziana Life Sciences LTD, is testing whether nasal foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS).1 The study is listed as not yet recruiting, with an estimated start date of 2026-07-25 and plans to enroll about 44 adults aged 18 to 75 with ALS.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.